Carter Julian Ward - Jan 19, 2022 Form 4 Insider Report for Enveric Biosciences, Inc. (ENVB)

Role: Chief Financial Officer
Signature: /s/ Carter Julian Ward
Stock symbol: ENVB
Transactions as of: Jan 19, 2022
Transactions value $: $0
Form type: 4
Date filed: 1/25/2022, 03:57 PM
Previous filing: May 27, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ENVB	Restricted Stock Units	Award	$0	+744K		$0.00	744K	Jan 19, 2022	Common Stock	744K		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the restricted stock units (the "RSUs") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock.
F2	50% of the RSUs shall vest over 4 years in equal annual installments, with the first tranche to vest on January 19, 2023. 50% of the RSUs shall vest in 3 approximately equal tranches on each of December 31, 2022, 2023 and 2024, if the Company's average VWAP (calculated as the average over the fourth calendar quarter of each of 2022, 2023 and 2024, as applicable, of the daily volume weighted average price of a share of common stock), exceeds $1.72, $1.89, $2.08, respectively.

Content

Represents the restricted stock units (the "RSUs") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the "Company") 2020 Long-Term Incentive Plan. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock.

50% of the RSUs shall vest over 4 years in equal annual installments, with the first tranche to vest on January 19, 2023. 50% of the RSUs shall vest in 3 approximately equal tranches on each of December 31, 2022, 2023 and 2024, if the Company's average VWAP (calculated as the average over the fourth calendar quarter of each of 2022, 2023 and 2024, as applicable, of the daily volume weighted average price of a share of common stock), exceeds $1.72, $1.89, $2.08, respectively.